We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Did you know? You can double click on a word to look it up on TermGallery.
Meanings of treat rare in anglès
We have no meanings for "treat rare" in our records yet.
Usage of treat rare in anglès
1
Biomarin produces drugs to treatrare genetic diseases that mostly affect children.
2
Drug-buying agency Pharmac is to fund two new medicines to treatrare illnesses.
3
Both are development-stage companies that are aiming to treatrare diseases, among other conditions.
4
Horizon has invested heavily in building a franchise to treatrare diseases in recent years.
5
The European Union grants orphan designation for medicines to treatrare but very serious conditions.
6
Orphan drug status is given to drugs that have the potential to treatrare diseases.
7
Orphan drug status is given to to drugs that have the potential to treatrare diseases.
8
Both drugs treatrare genetic disorders.
9
Many pharmaceutical firms have been pursuing gene-therapy companies that promise to treatrare, debilitating diseases by correcting DNA flaws.
10
One drug already in clinical trials is rapamycin, which is normally used to aid organ transplants and treatrare cancers.
11
In its most recent budget the Trudeau government promised modest changes, including new funds for expensive drugs that treatrare diseases.
12
Genzyme, best known for its so-called orphan drugs to treatrare genetic diseases, said mipomersen would fit the company's specialty focus.
13
Genzyme is the world's fourth-biggest biotechnology company, whose drugs to treatrare genetic disorders are some of the most expensive ever made.
14
Orphan drug status is granted by the U.S. Food and Drug Administration to drugs that have the potential to treatrare diseases.
15
Genzyme, which is best known for its so-called orphan drugs to treatrare genetic diseases, said mipomersen would fit the company's specialty focus.
16
Drugmaker Baxalta Inc has signed a deal with privately held Symphogen under which the companies will develop immuno-oncology drugs to treatrare cancers.